News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,615 Results
Type
Article (13904)
Company Profile (101)
Press Release (251610)
Section
Business (88390)
Career Advice (465)
Deals (15437)
Drug Delivery (66)
Drug Development (36613)
Employer Resources (49)
FDA (6293)
Job Trends (6265)
News (150753)
Policy (14131)
Tag
Academia (447)
Alliances (23289)
Alzheimer's disease (375)
Approvals (6315)
Artificial intelligence (92)
Bankruptcy (146)
Best Places to Work (4439)
Breast cancer (70)
Cancer (513)
Cardiovascular disease (54)
Career advice (406)
Cell therapy (73)
Clinical research (30771)
Collaboration (283)
Compensation (115)
COVID-19 (756)
C-suite (96)
Data (517)
Diabetes (68)
Diagnostics (1322)
Drug discovery (49)
Drug pricing (61)
Earnings (31934)
Events (37416)
Executive appointments (322)
FDA (6618)
Funding (176)
Gene therapy (90)
GLP-1 (324)
Government (1293)
Healthcare (3617)
Infectious disease (784)
Inflammatory bowel disease (54)
Interviews (59)
IPO (5906)
Job creations (2053)
Job search strategy (372)
Layoffs (175)
Legal (3458)
Lung cancer (71)
Manufacturing (126)
Medical device (1288)
Medtech (1290)
Mergers & acquisitions (9676)
Metabolic disorders (218)
Neuroscience (522)
NextGen: Class of 2025 (1635)
Non-profit (605)
Northern California (617)
Obesity (124)
Opinion (116)
Patents (91)
People (28873)
Pharmaceutical (64)
Phase I (8010)
Phase II (13017)
Phase III (11682)
Pipeline (296)
Policy (53)
Postmarket research (1402)
Preclinical (3200)
Radiopharmaceuticals (118)
Rare diseases (146)
Real estate (2679)
Regulatory (10077)
Research institute (571)
Resumes & cover letters (55)
Southern California (613)
Startups (1637)
United States (6159)
Vaccines (136)
Weight loss (89)
Date
Today (6)
Last 7 days (287)
Last 30 days (1003)
Last 365 days (12326)
2025 (2021)
2024 (12510)
2023 (14263)
2022 (19595)
2021 (20098)
2020 (19116)
2019 (15244)
2018 (12075)
2017 (13956)
2016 (13197)
2015 (15518)
2014 (12536)
2013 (10646)
2012 (11444)
2011 (11955)
2010 (10899)
Location
Africa (313)
Asia (20055)
Australia (2599)
California (1477)
Canada (814)
China (193)
Colorado (61)
Connecticut (61)
Delaware (48)
Europe (39271)
Florida (263)
Illinois (166)
Indiana (117)
Japan (75)
Kansas (53)
Maryland (224)
Massachusetts (1261)
Minnesota (81)
New Jersey (630)
New York (421)
North Carolina (349)
Northern California (617)
Pennsylvania (373)
South America (501)
Southern California (613)
Texas (194)
Virginia (62)
Washington State (101)
265,615 Results for "marij pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
MariJ Pharmaceuticals, Inc. Receives Patent # 10561693
Acacia Diversified Holdings, Inc. (“Acacia” or the “Company”) (OTCQB: ACCA), an emerging hemp Company, through its wholly owned subsidiaries, MariJ Pharmaceuticals, Inc. www.marijinc.com (MariJ), and Eufloria Medical of Tennessee, Inc. www.eufloriamedical.com
January 30, 2020
·
3 min read
Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, announced that MIRA-55, has been determined by the U.S. Drug Enforcement Administration (DEA) not to be a controlled substance or listed chemical under the Controlled Substance Act and its governing regulations.
May 29, 2024
·
6 min read
Layoffs
Marinus Pharmaceuticals Lays Off 45% of Employees
The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.
November 14, 2024
·
1 min read
·
Angela Gabriel
Press Releases
Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales
February 25, 2025
·
9 min read
Press Releases
Eupraxia Pharmaceuticals Announces CFO Succession
February 18, 2025
·
8 min read
Press Releases
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
February 24, 2025
·
1 min read
Press Releases
JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors
February 20, 2025
·
13 min read
Press Releases
CNS Pharmaceuticals Announces Reverse Stock Split
February 19, 2025
·
4 min read
Layoffs
X4 Pharmaceuticals Stumbles Again, Laying Off 30% of Workforce
The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last year received FDA approval to treat WHIM syndrome, in the larger patient population with chronic neutropenia.
February 6, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy
February 25, 2025
·
10 min read
1 of 26,562
Next